190 related articles for article (PubMed ID: 8535320)
1. The role of antibodies to IL-2 receptor and Asialo GM1 on graft-versus-leukemia effects induced by bone marrow allografts in murine B cell leukemia.
Weiss L; Reich S; Slavin S
Bone Marrow Transplant; 1995 Sep; 16(3):457-61. PubMed ID: 8535320
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):153-8. PubMed ID: 10641573
[TBL] [Abstract][Full Text] [Related]
4. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
5. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.
Zeis M; Uharek L; Glass B; Gaska T; Gassmann W; Mueller-Ruchholtz W
Bone Marrow Transplant; 1994 Nov; 14(5):711-5. PubMed ID: 7889004
[TBL] [Abstract][Full Text] [Related]
6. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
Cohen P; Vourka-Karussis U; Weiss L; Slavin S
J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438
[TBL] [Abstract][Full Text] [Related]
7. The effects of polyinosinic:polycytidylic acid (pI:C) on the graft-vs-host (GVH) reaction. II. Increased NK-mediated rejection on C57BL/6 lymphocytes by (C57BL/6 X A)F1 mice.
Peres A; Nestel FP; Seemayer TA; Lapp WS
J Immunol; 1986 Dec; 137(11):3420-7. PubMed ID: 3537120
[TBL] [Abstract][Full Text] [Related]
8. Evidence for a possible role of Asialo-GM1-positive cells in the graft-versus-leukemia repression of a murine type-C retroviral leukemia.
OKunewick JP; Kociban DL; Machen LL; Buffo MJ
Bone Marrow Transplant; 1995 Sep; 16(3):451-6. PubMed ID: 8535319
[TBL] [Abstract][Full Text] [Related]
9. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
10. Treatment of BCL1 leukemia by transplantation of low density fractions of allogeneic bone marrow and spleen cells.
Palathumpat V; Holm B; Dejbakhsh-Jones S; Strober S
J Immunol; 1992 May; 148(10):3319-26. PubMed ID: 1578152
[TBL] [Abstract][Full Text] [Related]
11. Natural killer cells as effector cells of graft-versus-leukemia activity in a murine transplantation model.
Uharek L; Glass B; Gaska T; Zeiss M; Gassmann W; Löffler H; Müller-Ruchholtz W
Bone Marrow Transplant; 1993; 12 Suppl 3():S57-60. PubMed ID: 8124260
[TBL] [Abstract][Full Text] [Related]
12. A subset of asialo GM1+ cells play a protective role in the occurrence of graft-versus-host disease in mice.
De Ruysscher D; Sobis H; Vandeputte M; Waer M
J Immunol; 1991 Jun; 146(12):4065-70. PubMed ID: 1828259
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of GVL effect with rhIL-2 following BMT in a murine model for acute myeloid leukemia in SJL/J mice.
Vourka-Karussis U; Karussis D; Ackerstein A; Slavin S
Exp Hematol; 1995 Mar; 23(3):196-201. PubMed ID: 7875238
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-7 induced facilitation of immunological reconstitution of sublethally irradiated mice following treatment with alloreactive spleen cells in a murine model of B-cell leukemia/lymphoma (BCL1).
Abdul-Hai A; Weiss L; Ben-Yehuda A; Ergas D; Shapira MY; Slavin S
Bone Marrow Transplant; 2007 Nov; 40(9):881-9. PubMed ID: 17704792
[TBL] [Abstract][Full Text] [Related]
15. Effect of cyclosporine A and methylprednisolone on the graft-versus-leukemia effects across major histocompatibility barriers in mice following allogeneic bone marrow transplantation.
Weiss L; Reich S; Slavin S
Bone Marrow Transplant; 1990 Oct; 6(4):229-33. PubMed ID: 2085696
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to upregulate antitumor effects and downregulate antihost responses.
Ji YH; Weiss L; Zeira M; Abdul-Hai A; Reich S; Schuger L; Slavin S
Bone Marrow Transplant; 2003 Sep; 32(5):495-504. PubMed ID: 12942096
[TBL] [Abstract][Full Text] [Related]
17. Induction of bone marrow allograft rejection and hybrid resistance in nonresponder recipients by antibody: is there evidence for a dual receptor interaction in acute marrow graft rejection?
Dennert G; Anderson CG; Warner J
J Immunol; 1986 Jun; 136(11):3981-6. PubMed ID: 3517162
[TBL] [Abstract][Full Text] [Related]
18. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].
Li Y; Guo K; Chen Y; Song Z; Li J; Deng L
Zhonghua Xue Ye Xue Za Zhi; 2002 Aug; 23(8):411-4. PubMed ID: 12411044
[TBL] [Abstract][Full Text] [Related]
19. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy.
Weiss L; Reich S; Slavin S
Cancer Invest; 1992; 10(1):19-26. PubMed ID: 1735011
[TBL] [Abstract][Full Text] [Related]
20. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
